advanced search

INJECTION

HOW LARGE-VOLUME WEARABLES REVOLUTIONISE THE PATIENT EXPERIENCE
WEARABLES
Victoria Morgan
West Pharmaceutical Services
HOW LARGE-VOLUME WEARABLES REVOLUTIONISE THE PATIENT EXPERIENCE
Victoria Morgan looks at how the combination of large-volume medicines and the trend for wearable devices is transforming life for patients, highlighting the company's new-generation SmartDose 10 mL platform.
MITIGATING RISK TO DELIVER SUCCESS IN HIGH-VOLUME WEARABLE DEVICES
WEARABLES
Catherine Thacker
MITIGATING RISK TO DELIVER SUCCESS IN HIGH-VOLUME WEARABLE DEVICES
Catherine Thacker and Bill Jaworski discuss risk reduction solutions in the manufacturing architecture for wearable injectors, including an example where autonomous intelligent vehicles and ATS‘s real-time industrial IoT manufacturing intelligence system, Illuminate®, were employed.
THE CHALLENGES OF VERIFYING A WEARABLE INFUSOR
EXPERT VIEW
Michael Penman
THE CHALLENGES OF VERIFYING A WEARABLE INFUSOR
Michael Penman shows why it is important to verify body-worn infusor performance, highlighting the challenges and learnings from an example where Team Consulting was tasked with the design and verification of one such wearable device.
A QUICK GUIDE TO USABILITY FOR WEARABLE INJECTORS
EXPERT VIEW
Cory Costantino
A QUICK GUIDE TO USABILITY FOR WEARABLE INJECTORS
Cory Costantino and Lauren Fennelly list some typical steps a user might take while using wearable injectors, providing tips and points to note at each step, including design tips that might pre-empt potential interaction problems, and points to consider when conducting usability testing.
2019 PDA UNIVERSE OF PRE-FILLED SYRINGES AND INJECTION DEVICES PREVIEW
CONFERENCE SHOWCASE
Dr Falk Klar
PDA
2019 PDA UNIVERSE OF PRE-FILLED SYRINGES AND INJECTION DEVICES PREVIEW
PDA Europe presents the 16th edition of its signature event Universe of Pre-filled Syringes & Injection Devices – an important conference for people working in the fields of parenteral drug, and device, development, covering solutions to challenges regarding new developments, and regulatory and industry trends.
EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES
INDUSTRIALISATION
Gilbert Fluetsch
SHL Medical
EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES
Gilbert Fluetsch and Lucy Chung look at how automation and assembly services can best evolve and adapt to industry standards and market demands, whilst delivering consistently at high quality and in a timely manner.
Z.BLIZZARD AUTOMATION SYSTEM – IT DOESN’T GET MORE TAILOR-MADE THAN THIS
INDUSTRIALISATION
Berthold Schopferer
Z.BLIZZARD AUTOMATION SYSTEM – IT DOESN’T GET MORE TAILOR-MADE THAN THIS
Berthold Schopferer explains how the Zahoransky’s integrated syringe manufacturing and assembly equipment allows maximum customisation and full customer involvement.
Cecile Halte, BD
INTERVIEW
Cecile Halte
BD (Becton Dickinson & Company)
Cecile Halte, BD
In this interview, Cécile Halté, Senior Program Manager, Acute Care Segment, for BD Medical – Pharmaceutical Systems. discusses validation studies of the BD Sterifill Advance™ plastic prefilled syringe, which is intended for use in the hospital setting by healthcare professionals either for manual bolus injections, or with infusion pumps.
A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS
INDUSTRIALISATION
Michael Wiglenda
Gerresheimer
A FIVE-STEP APPROACH TO INNOVATION IN DRUG DELIVERY SYSTEMS
Michael Wiglenda explains Gerresheimer’s industrialisation offering and the five-step Gate-Model that guides its innovation process.
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
INDUSTRIALISATION
Steve Wardell
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
Steve Wardell and Catherine Thacker explore how machine learning technology is enabling the automation of challenging, or previously impossible, manual inspections.
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
EXPERT VIEW
Shaul Eitan
CUSTOMISED INFUSION PUMPS: THE FUTURE OF SELF-ADMINISTRATION?
Shaul Eitan explores the challenges of home infusion and examines how customisation and connectivity could help provide a solution.
I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS
CONNECTIVITY
Dr Andreas Schneider
Ypsomed
I SPY WITH MY LITTLE EYE: EYE TRACKING DRIVES PATIENT-CENTRED DEVELOPMENT OF CONNECTED SYSTEMS
The development of connected self-injection systems is driving industry to rethink its current approaches to patient-centred new product development. Andreas Schneider summarises a recent field study that used eye tracking for the formative usability testing of SmartPilot for YpsoMate.
MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY
CONNECTIVITY
Dr Ramin Rafiei
SHL Medical
MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY
Ramin Rafiei argues that connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
CONNECTIVITY
Eric Dessertenne
Biocorp
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
CONNECTIVITY
Thierry Decock
Nemera
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.
MIRCEA DESPA & DOUG McCLURE, BD
INTERVIEW
Dr Mircea Despa
BD (Becton Dickinson & Company)
MIRCEA DESPA & DOUG McCLURE, BD
In this interview, Dr Despa and Mr McClure discuss BD’s approach to connecting devices in its portfolio to meet patient, pharma and other stakeholder requirements. Their discussion focuses in particular on safety and security, highlighting the connected wearable injector, BD Libertas™ with Smart Option, as an example.
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
CONNECTIVITY
Matt Jones
DCA
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
Matt Jones summarises some of the key challenges and opportunities in the development of connected drug delivery devices, focusing in detail on deciding what a connected drug delivery device should do, designing for a coin cell, direct cellular connection and antenna design.
USER-CENTRED DEVICE CONNECTIVITY
EXPERT VIEW
Mark Tunkel
USER-CENTRED DEVICE CONNECTIVITY
Mark Tunkel and Carolyn Rose discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
CONNECTIVITY
Neil Williams
Phillips Medisize
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
Neil Williams describes the potential connected drug delivery systems hold to address serious challenges in healthcare, including poor adherence, and also deliver substantial value, and outlines the company’s highly scalable enterprise platform, the Connected Health Platform.
ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES
CONNECTIVITY
Craig Baker
Noble
ADHERENCE TO SELF-INJECTION REGIMENS CAN BE ENHANCED BY CONNECTED DEVICES
 Craig Baker looks at the factors contributing to non-adherence and explores how connected devices can help patients follow their self-injection regimens.
ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES
CONNECTIVITY
Tsachi Shaked
ADDING CONNECTIVITY TO DRUG DELIVERY DEVICES
Tsachi Shaked explores how – as the trend towards moving healthcare from the hospital to the home continues – connectivity in drug delivery devices may be changing from being the exception to the rule.
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
WEARABLES
Jesper Roested
A PATIENT CENTRIC AND PHARMA COMPANY CENTRIC PREFILLED WEARABLE BOLUS INJECTOR
Jesper Roested explains why the pharma/biotech drug development process often means device selection occurs after Phase II despite the advantages of earlier selection being well understood, and how this then precludes the selection of novel primary packaging and delivery systems.
COMPANY SHOWCASE: Cristal Therapeutics
INJECTION
Dr Cristianne Rijcken
COMPANY SHOWCASE: Cristal Therapeutics
Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE<sup>®</sup> HPB-LB PARENTERAL GRADE
INJECTION
Dr Elham Blouet
Roquette
A NEW MULTI-COMPENDIA MODIFIED BETA-CYCLODEXTRIN, KLEPTOSE® HPB-LB PARENTERAL GRADE
Elham Blouet introduces the latest addition to the company’s range of beta-cyclodextrins, and outlines the benefits it brings.
Top